Deciphera gets Canadian approval for QINLOCK for fourth-line gastrointestinal stromal tumour

Deciphera announces Health Canada’s authorization of QINLOCK (ripretinib) for the treatment of fourth-line gastrointestinal stromal tumour. (Credit: skeeze from Pixabay)